CGON CG ONCOLOGY INC

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences:

  • Cantor Global Healthcare Conference – presenting Friday, September 5, 2025, at 10:20am ET in New York, NY
  • Morgan Stanley 23rd Annual Global Healthcare Conference – presenting Tuesday, September 9, 2025, at 7:45am ET in New York, NY



Interested parties may access the live audio webcast for this conference from the of the company's website at . The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit:

Contacts:

Media

Sarah Connors

Vice President, Communications and Patient Advocacy, CG Oncology

Investor Relations

Megan Knight

Vice President, Investor Relations, CG Oncology



EN
29/08/2025

Underlying

CGONCG ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CG ONCOLOGY INC

 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology Continues to Demonstrate Best-in-Disease Durability and To...

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months - Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month responders remained disease free at 24 Months -- Safety profile remains consistent - IRVINE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage cl...

September 5, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology Completes Enrollment in PIVOT-006 – Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines – IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has com...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology’s Executive Leadership to Participate in Upcoming Investor...

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences: Cantor Global Healthcare Conf...

August 29, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

CG Oncology Reports Second Quarter 2025 Financial Results and Provides...

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - - Announced unanimous verdict that CG Oncology owes no future royalties or other payments to ANI Pharmaceuticals - IRVINE, Calif., Aug. 08, 20...

August 8, 2025 1 EN
 PRESS RELEASE
Free
CGON CG ONCOLOGY INC

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology...

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a jury in the Superior Court of the State of Delaware (the “Court”) unanimously found in favor of CG Oncology on all claims in a March 2024 lawsuit brought by ANI Pharmaceuticals, ...

July 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch